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SUMMARY 
Antiretroviral drug resistance remains an important and a growing challenge in HIV management as it almost 
always lead to treatment failure.  Sex workers face persistent exposures to the different HIV-1 variants and 
in turn pose a risk of transmission to the general population and measuring drug resistance in this 
population may serve as a measure for the risk of transmission of these strains to drug naïve populations. 
The objective of this study was therefore to determine the pattern and prevalence of HIV-1 drug resistance 
mutations in a cohort of female sex workers in Nairobi, Kenya. Plasma from 60 female sex workers on 
antiretroviral treatment for over six months was analyzed by amplification and sequencing of the reverse 
transcriptase - pol region. Five samples (8.3%) showed antiretroviral resistance-associated mutations. One 
sample (1.7%) showed mutations conferring resistance only to the NNRTI class, 2 samples (3.3%) showed 
mutations conferring resistance only to the NRTI class while 2 samples (3.3%) showed mutations conferring 
resistance to both NRTI and NNRTI classes. Phylogenetic analysis revealed HIV-1 subtype A1 (96.7%) and 
HIV-1 subtype D (3.3%). The prevalence rate of 8.3% for reverse transcriptase-associated resistance 
mutations was observed. This is a lower rate than has been reported from studies among antiretroviral 
(ARV)-treated individuals in the country.  
[Afr J Health Sci. 2013; 26:291-302] 
 
 African Journal of Health Sciences, Volume 26, Number 4, October-December 2013 292 
Introduction 
One of the major responses to the HIV/AIDS crisis in 
Kenya was the introduction of a national policy for 
infected persons to access antiretroviral therapy 
(ART), which led the Ministry of Health to develop a 
work programme and a national standard regimen[1]. 
With donor support, ART coverage rose progressively 
from under 5% in 2004, 12% in 2005, 28% in 2006 
to nearly 40% by end of 2007[2]. By the end of 
September 2008, 229,700 people were on ART 
through programmes such as The President's 
Emergency Plan for AIDS Relief (PEPFAR) in 
Kenya[3]. Over 400,000   HIV/AIDS   patients   were 
  receiving   antiretroviral treatment by the end of 
2010[4] and this number grew to 600,000 in 2012 [5]. 
The current standard regimen for first-line therapy in 
Kenya consists of two Nucleoside Reverse 
Transcriptase Inhibitors (NRTI) usually tenofovir 
disoproxil fumarate (TDF) or azidovudine (AZT), 
lamuvudine (3TC) and one Non-Nucleoside Reverse 
Transcriptase Inhibitor (NNRTI) efevirenz (EFV) or 
nevirapine (NVP)[6]. Antiretroviral therapy is initiated 
following the current World Health Organization 
(WHO) recommendations for initiation of early 
treatment[4]. 
The recent expansion of ART in middle and low-
income has resulted in increased development, 
transmission and prevalence of drug resistant HIV-1 
strains[7] especially seen in countries that pioneered 
antiretroviral therapies[8, 9]. Data from treated 
prevention of mother to child transmission (PMTCT) 
and paediatric cohorts in Kenya have shown drug 
resistance rates as high as 30%[10, 11]. A study 
involving patients from the general population 
attending a Comprehensive HIV Care Centre (CCC) at 
a hospital in Mombasa, Kenya reported reverse 
transcriptase inhibitor (RTI) drug resistance in 87.5% 
of the population sampled [12]. 
The HIV-1 genome is highly variable ranging from 
40% variation in the envelope gene to 8–10% 
variation in the pol, gag, and integrase genes. 
Exposure to antiretroviral drug pressure contributes to 
development of mutations and the number of 
mutational changes in the RT gene has been shown 
to increase from a median of 4 in untreated 
individuals to 14 in heavily treated individuals [13]. 
Outside of the mutations designated by the 
International AIDS Society  (IAS), additional mutations 
known as accessory mutations have been associated 
with exposure to ARV [14] and may influence 
susceptibility to therapy and/or have either an inverse 
or a direct correlation to resistance [15] .  
The bulk of new HIV infections in sub-Saharan Africa 
are attributable to unprotected heterosexual 
intercourse, including transactional sex. The greatest 
risk factor infection with HIV in the region is 
unprotected sex with multiple partners[16]. Also most 
at risk populations (MARPs) who include female sex 
workers, and their clients, men who have sex with 
men and injecting drug users play a significant role in 
driving the HIV epidemic in Kenya. It is estimated that 
14% of new HIV infections in Kenya are linked to sex 
workers, their clients and other sex partners within the 
network[17]. However rates of drug resistance among 
sex workers in Kenya are unknown, yet this is an 
important population in HIV transmission and control 
dynamics such as antiretroviral resistance. We 
undertook this study to identify antiretroviral resistance 
genotypes in a cohort of highly exposed female sex 
workers in Nairobi, Kenya. 
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Materials and methods 
Adult women drawn from a sex worker cohort based 
in the Majengo slum, Nairobi and managed by the 
University of Nairobi/University of Manitoba 
collaborative HIV group were considered for enrolment 
into the study, after giving informed consent. A total of 
84 participants who had been on ART for six months 
or more were enrolled for this cross-sectional study. 
The specimens that were analysed for this study were 
collected between December 2007 and March 2008. 
Clearance to carry out this study was sought from and 
granted by the KEMRI Scientific Steering Committee 
(Ref: ESACIPAC/SCC/2873) and the KEMRI Ethical 
Review Committee (Ref: KEMRI/RES/7/3/1).  
Ten millilitres of blood was collected in tubes 
containing Ethylenediaminetetraacetic acid (EDTA) 
anticoagulant. Ribonucleic acid (RNA) was isolated 
from plasma using The QIAamp® Viral RNA Mini Kit 
(Qiagen Inc., Chatsworth, CA) following the 
manufacturer’s protocol and complementary DNA 
(cDNA) was synthesised using The High Capacity 
cDNA Reverse Transcription kit (Applied Biosystems, 
foster City, CA) according to manufacturer’s 
guidelines. 
A region of the pol-RT gene corresponding to nt 
2480– nt 3180 of HIV-1 HXB2 was amplified by 
nested Polymerase Chain Reaction (PCR) with primer 
sets, RT18 
(5’GGAAACCAAAAATGATAGGGGGAATT 
GGAGG-3’) and KS104 (5’-TGACTTGCCCAATTT 
AGTTTTCCCACTAA-3’) in the first round, and 
KS101 (5’-GTAGGACCTACACCTGTTCAACATA 
ATTGGAAG-3’) and KS102 (5’-CCCATCCAAAGA 
AATGGAGGAGGTTCTTTCTGATG-3’) in the sec- 
ond round[18]. Amplification conditions were as 
follows; a hold at of 95 º C for 2 minutes, 35 cycles of 
95 º C for 30 seconds, 55 º C for 30 seconds, and 72 
º C for 1 minute and a final extension at 72 º C for 10 
minute. Agarose gel electrophoresis and ethidium 
bromide staining of samples was used to confirm PCR 
amplification. Amplicons were sequenced directly and 
analyzed using BigDye® v3.1 sequencing technology 
in an ABI 3130xl Genetic Analyzer (Applied 
Biosystems, Foster City, CA) as described 
previously[19]. 
Reverse transcriptase nucleotide sequences 
generated (697bps) were translated into the 
corresponding aminoacids and submitted to the 
Stanford HIV drug resistance database 
(http://hivdb.stanford.edu) and in the National Centre 
for Biotechnology Information- Genbank Database 
(http://www.ncbi.nlm.nih.gov/Genbank/)for evaluation 
and identification mutations as well as interpretation of 
resistance. The 2008 International AIDS Society-USA 
(IAS-USA) guidelines were used to define 
antiretroviral resistance-associated mutations for 
Reverse Transcriptase Inhibitors (RTI) [20]. 
The National Centre for Biotechnology Information 
(NCBI) subtyping program  
(http://www.ncbi.nih.gov/projects/genotyping/formpag
e.cgi), the HIV Blast tool  
(http://www.hiv.lanl.gov/content.hivdb/BASIC_BLAST/
basic_blast.html) and the REGA HIV-1 Subtyping tool 
(http://www.bioafrica.net/subtypetool/) were used for 
initial rapid subtype screening before confirmation by 
phylogenetic analysis using reference sequences from 
The Los Alamos website  
(http://www.hiv.lanl.gov/content.hivdb/SUBTYPE_RE
F/align.html).  
Sequence alignment was done using Clustal W and 
the phylogenetic tree generated and viewed in 
Treeview® by the Neighbour Joining (NJ) method 
based on the bootstrapped Kimura 2-parameter. 
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The sequences have been deposited in the GenBank 
database with accession numbers HM596786-
HM596845 
Results 
Majority of participants were on first line therapy 
typically, nevirapine (NVP), lamivudine (3TC) and 
stavudine (d4T). One participant received combination 
protease inhibitor, Kaletra with tenofovir and 
zidivudine. The mean age of the participants was 30 
yrs with mean of 6 years involvement in sex-work. 
The CD4 cell counts at sample collection ranged from 
48-687 cells/ µl. The mean time of treatment was 88 
weeks (Standard Deviation 42.3) (Table 1).  
Table 1: Baseline characteristics of participants  
 
 
Sixty samples out of the 84 collected were 
successfully amplified sequenced and analysed. 
Sequence alignment and phylogenetic analysis 
showed that 58 isolates (96.7%) were HIV-1 subtype 
A1 while 2 isolates (3.3%) were HIV-1 subtype D. 
Samples that were found to be HIV-1 subtype AI 
showed further diverse sub-clustering in the 
Neighbour-Joining tree (Fig. 1) suggesting divergence 
in the HIV-1 subtype A1 among the study subjects. 
Of the 60 samples analysed, 55 (91.6%) were 
wildtype while 5 (8.3%) showed mutations conferring 
resistance to reverse transcriptase inhibitors indicating 
an HIV-1 drug resistance prevalence rate of 8.3%. 
Out of the 5 samples showing RTI resistance - 
associated mutations, 3 (5%) were infected with HIV-
1 subtype A1 while 2 (3.3%), were infected with HIV-
1 subtype D (Table 2a). 
Resistance to NRTIs, most commonly lamivudine was 
identified in four samples while resistance to NNRTIs, 
most commonly nevirapine was identified in three 
samples. Complete class resistance to NNRTI was 
identified in 2 samples, (3.3%), both, HIV-1 subtype 
D. Complete class resistance was not observed for 
the NRTI class. Two samples (3.3%), both HIV-1 
subtype A1, showed susceptibility to all drugs in the 
NNRTI class while 1 sample (1.7%) was susceptible 
to all NRTI. There was no statistically significant 
difference in time of exposure to ART between the 
participants who developed resistance and those that 
did not (mean 64 weeks versus 90 weeks, p= 0. 192) 
(Table 2a). 
The reverse transcriptase inhibitor-associated major 
mutations G190A, M184V, Y181C, T215S, V118I, 
K101E, D67N and D67A were detected. G190A, 
Y181C and K101E compromise efficacy to NNRTI 
while T215S, V118I, D67N, D67A and M184V 
compromise efficacy to NRTI. G190A, M184V and 
Y181C appeared most frequently (40%) in the 5 
samples (Table 2a). The three mutations occurred 
together (in combination with others) in isolate 
ML2572 while two of these mutations, M184V and 
Y181C occurred together in isolate ML1935 (Table 
2b).  
Minor mutations and polymorphisms were detected in 
all the 60 isolates that were analysed. V60I was 
present in all (100%) of the samples. K11T, K20R, 
V21I, V35T, T39R/I, V60I, K122E, D123S, K173A/V, 
Q174K, V179I, G196E, T200V, Q207A/E/L/D and 
R211S/H/K were present in over 50% of the isolates. 
Characteristic N=60 
Age (mean years) 30 years 
Time engaged in sex work 
(mean years) 
6 years 
Time on treatment (mean 
weeks) 
88 weeks (SD 
42.3) 
CD4+ T cell count (Range 
cells/mm3) 
48-687 cells/mm3 
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Others present in lower frequencies were IL2, P4H, 
E6Q/A/G, K22N, Q23L, E28K, E40D, K23R, K49R, 
I50M, R78G, D86G, L92I, H96P, P97R, K102R, 
T107P, D113E, T131P, P133L, S134G, I1357, 
N136T, E138G, T146S, S162G, E169D, F171L, 
D177E, I178M/V, R199T, I202V, E203G, E204G, 
R206N, H208R, L209A, L210X, W212V, F214X/L/I 
and T215X.
 
Table 2a: Important characteristics of samples showing RTI resistance-associated mutations 
 
* - Drugs for which the mutations shown compromise efficacy 
 
 
 
 
 
 
Patient 
ID 
ART at study point Length of 
time on  
ART (wks)  
HIV-1 
Subtype 
RTI 
resistance 
mutations 
Class: NRTI Class: NNRTI 
ML1756 NVP/d4T 30/3TC 34 A1 T2I5S ABC, AZT, d4T*, 
ddI, TDF 
None 
ML1932 NVP/d4T 40/3TC 
 
141 A1 G190A None NVP*, ETR, EFV 
ML1935 NVP/d4T 40/3TC 60 D M184V, 
Y181C 
3TC*, ABC, FTC All* (DLV, EFV, ETR, 
NVP) 
ML2572 TDF/KALETRA/ 
AZT 
51 D D67N, 
V118I, 
M184V, 
K101E, 
Y181C, 
G190A 
3TC, ABC, AZT*, 
d4T, ddI, FTC 
All* (DLV, EFV, ETR, 
NVP) 
ML2661 NVP/d4T 30/ 3TC 
 
34 A1 D67A d4T*, 3TC*, AZT None 
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Table 2b: Mutation map for samples showing RTI resistance-associated mutations 
 Nucleoside RT Inhibitor (NRTI) Resistance Mutations Non-Nucleoside RT Inhibitor (NNRTI) Resistance Mutations 
Patient 
ID 
CD4+ T cell 
Count 
41 
M 
65 
K 
67 
D 
69 
T 
70 
K 
74 
L 
75 
V 
77 
F 
115 
Y 
116 
F 
184 
M 
210 
L 
215 
T 
219 
K 
100 
L 
101 
K 
103 
K 
106 
V 
179 
V 
181 
Y 
188 
Y 
190 
G 
225 
P 
230 
M 
ML 
1756 276             S            
ML 
1932 407                      A   
ML 
1935 103           V              
ML 
2572 157   N        V     E    C  A   
ML 
2661 319   N                      
 297 
 
Figure 1 
 
Phylogenetic analysis of HIV-1 RT (corresponding to 
nt 2480– nt 3180 of HIV-1 HXB2) sequences from 
ARV-treated female sex workers in Nairobi Kenya. A 
blue circle marks the reference sequences, red circle 
marks sequences that are subtype D and a black 
circle marks sequences that are subtype A1. An ML 
number indicates study samples 
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Discussion 
This study found the prevalence of RTI-associated 
mutations to be 8.3% in a population of ARV treated 
female sex workers sampled in 2008. This is the first 
study to identify antiretroviral resistance genotypes in 
a population engaged in sex work in Kenya. This 
prevalence is low relative to previous studies on 
treated individuals attending CCC and PMTCT clinics 
within Kenya [11]. More recent studies in Kenyan 
cohorts have however reported an even higher risk for 
development of antiretroviral resistance mutations 
even in populations with short-term treatment [12, 
21]. Antiretroviral therapy was introduced into the 
Majengo cohort less than two years prior to sampling 
for this study and this could account for the much 
lower prevalence observed. The samples studied 
were collected at different times in the treatment 
courses of individual patients, ranging from 34 weeks 
to 149 weeks on treatment. The length of time on 
treatment however did not appear to have an 
influence on the number of antiretroviral resistance 
mutations identified. This is despite findings that show 
that prevalence of drug resistance is directly 
proportional to the length of time of exposure to 
ART[22-25]. 
HIV-1 subtype A1 was predominant in this population 
at 96.7%, while HIV-1 subtype D was observed in 
3.3% of the women. This is consistent with previous 
studies that have shown HIV-1 subtype A to be the 
predominantly circulating subtype in various regions in 
Kenya [26-29]. The few studies on HIV-1 subtype 
distribution that have been carried out within the 
Majengo cohort show that HIV-1 subtype A 
predominates, followed by subtype D and a significant 
proportion of intersubtype recombinants [30, 31].  
A total of seven mutation points (at codons 67, 101 
118, 181, 184, 190 and 215) were identified in the 5 
samples with RTI-associated resistance mutations. 
Presence of the revertant mutation I/S at position 215 
suggests suboptimal therapeutic regimens that are 
unable to prevent development of resistance [32]. All 
participants with RTI-associated mutations showed 
evidence of resistance to at least one drug in their 
treatment regimen. Complete class resistance to 
NNRTI was observed in 40% of participants. NNRTI 
resistance occurs most often at lower levels of 
adherence to ART [33]. This, coupled with the 
occurrence of mutations that have been associated 
with suboptimal therapeutic regimens as mentioned 
above, suggests that adherence to ART in this 
population needs be monitored closely. 
V60I, which was detected in all 60 isolates that were 
analyzed, has been identified as a polymorphic amino 
acid residue specifically in HIV-1 subtypes A and D. 
Q207A and R211S have been identified in HIV-1 
subtype A and K49R in HIV-1 subtype D [34]. 
Mutations at positions K20, T39, V35, K122, D123, 
K173, Q174, V179, T200, Q207 and R211 have 
been have been shown to have a possible association 
with a decrease in phenotypic susceptibility to RTI. 
Mutations at positions K20 and K43 are associated 
with previous use of RTI with a correlation between 
the presence of K20R and the use of lamivudine while 
T39R was associated with the previous use of AZT 
and with the development of thymidine analog 
resistance [13, 15]. Fifty-nine of 60 participants in 
this study were on lamivudine and 28 were treated 
with AZT. 
A limitation to this study is that while these findings 
show the level of RTI-associated resistance in this 
population, the cause for the development of this 
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resistance cannot be conclusively identified. 
Development of antiretroviral resistance may be as a 
result of singular factors or interactions of factors such 
as levels of adherence to ART [35, 36] and levels of 
HIV RNA suppression [37, 38]. In this study, we were 
unable to collected data for both ART adherence and 
HIV RNA load. 
Conclusion 
The findings of this study corroborate those in earlier 
studies on subtype distribution in Kenya. 
Recombination analyses would be useful in extending 
the dataset on the Majengo cohort, in any follow-up 
studies. The drug resistance rate observed in this 
study though low for a population of treated 
individuals is of great public health significance 
because the sex worker population play an important 
role in transmission of antiretroviral resistant HIV-1 
genotypes.  
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